Daiichi Sankyo to take huge hit from Ranbaxy share slump
This article was originally published in Scrip
Executive Summary
Daiichi Sankyoexpects a significant negative impact on its full-year consolidated net profit from a multi-billion dollar write-down in the value of its majority holding inRanbaxy Laboratories.